当前位置: X-MOL 学术Intensive Care Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Sodium chloride or Plasmalyte-148 evaluation in severe diabetic ketoacidosis (SCOPE-DKA): a cluster, crossover, randomized, controlled trial
Intensive Care Medicine ( IF 38.9 ) Pub Date : 2021-10-05 , DOI: 10.1007/s00134-021-06480-5
Mahesh Ramanan 1, 2, 3, 4 , Antony Attokaran 5 , Lauren Murray 6 , Neeraj Bhadange 7 , David Stewart 8 , Gokulnath Rajendran 9 , Raju Pusapati 10 , Melissa Petty 1 , Peter Garrett 6 , Peter Kruger 11 , Sandra Peake 12 , Laurent Billot 3 , Balasubramanian Venkatesh 3, 13 ,
Affiliation  

Purpose

To determine whether treatment with Plasmalyte-148 (PL) compared to sodium chloride 0.9% (SC) results in faster resolution of diabetic ketoacidosis (DKA) and whether the acetate in PL potentiates ketosis.

Methods

We conducted a cluster, crossover, open-label, randomized, controlled Phase 2 trial at seven hospitals in adults admitted to intensive care unit (ICU) with severe DKA with hospital randomised to PL or SC as fluid therapy. The primary outcome, DKA resolution, was defined as a change in base excess to ≥ − 3 mEq/L at 48 h.

Results

Ninety-three patients were enrolled with 90 patients included in the modified-intention-to-treat population (PL n = 48, SC n = 42). At 48 h, mean fluid administration was 6798 ± 4850 ml vs 6574 ± 3123 ml, median anion gap 6 mEq/L (IQR 5–7) vs 7 mEq/L (IQR 5–7) and median blood ketones 0.3 mmol/L (IQR 0.1–0.5) vs 0.3 (IQR 0.1–0.5) in the PL and SC groups. DKA resolution at 48 h occurred in 96% (PL) and 86% (SC) of patients; odds ratio 3.93 (95% CI 0.73–21.16, p = 0.111). At 24 h, DKA resolution occurred in 69% (PL) and 36% (SC) of patients; odds ratio 4.24 (95% CI 1.68–10.72, p = 0.002). The median ICU and hospital lengths of stay were 49 h (IQR 23–72) vs 55 h (IQR 41–80) and 81 h (IQR 58–137) vs 98 h (IQR 65–195) in the PL and SC groups.

Conclusion

Plasmalyte-148, compared to sodium chloride 0.9%, may lead to faster resolution of metabolic acidosis in patients with DKA without an increase in ketosis. These findings need confirmation in a large, Phase 3 trial.



中文翻译:

氯化钠或 Plasmalyte-148 对严重糖尿病酮症酸中毒 (SCOPE-DKA) 的评估:一项集群、交叉、随机、对照试验

目的

确定与氯化钠 0.9% (SC) 相比,用 Plasmalyte-148 (PL) 治疗是否能更快解决糖尿病酮症酸中毒 (DKA),以及 PL 中的醋酸盐是否会增强酮症。

方法

我们在七家医院进行了一项集群、交叉、开放标签、随机、对照的 2 期试验,受试者为重症监护病房 (ICU) 的重症 DKA,医院随机分配至 PL 或 SC 作为液体疗法。主要结果,DKA 分辨率,定义为 48 小时时碱过量变化至 ≥ − 3 mEq/L。

结果

纳入了 93 名患者,其中 90 名患者包括在改良意向治疗人群中(PL n  = 48,SC n  = 42)。在 48 小时时,平均输液量为 6798 ± 4850 ml 与 6574 ± 3123 ml,阴离子间隙中值 6 mEq/L (IQR 5–7) vs 7 mEq/L (IQR 5–7) 和血酮中值 0.3 mmol/L (IQR 0.1–0.5) vs 0.3 (IQR 0.1–0.5) 在 PL 和 SC 组。96% (PL) 和 86% (SC) 的患者在 48 小时时 DKA 消退;优势比 3.93(95% CI 0.73–21.16,p  = 0.111)。24 小时时,69% (PL) 和 36% (SC) 的患者出现 DKA 消退;优势比 4.24(95% CI 1.68–10.72,p = 0.002)。PL 和 SC 组的 ICU 和住院时间中位数分别为 49 小时(IQR 23-72)与 55 小时(IQR 41-80)和 81 小时(IQR 58-137)与 98 小时(IQR 65-195) .

结论

Plasmalyte-148 与 0.9% 的氯化钠相比,可能会导致 DKA 患者代谢性酸中毒的更快消退,而不会增加酮症。这些发现需要在大型 3 期试验中得到证实。

更新日期:2021-10-06
down
wechat
bug